Keros Therapeutics (KROS) Misses Q4 EPS by 134c

Keros Therapeutics (NASDAQ: KROS) reported Q4 EPS of ($1.34), $1.34 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $140 thousand versus the consensus estimate of $0 .

For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• General Mills beats estimates as cost savings offset volumes
• AppLovin drops 3% as Edgewater analyst warns of stalled market share growth